The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3

[1]  D. Wiley,et al.  Invariant chain made in Escherichia coli has an exposed N-terminal segment that blocks antigen binding to HLA-DR1 and a trimeric C-terminal segment that binds empty HLA-DR1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  A. Goldrath,et al.  T cell recognition of major histocompatibility complex class II complexes with invariant chain processing intermediates , 1995, The Journal of experimental medicine.

[3]  Direct observation of disordered regions in the major histocompatibility complex class II-associated invariant chain. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  J. Drijfhout,et al.  Clip binds to HLA class II using methionine-based, allele-dependent motifs as well as allele-independent supermotifs. , 1995, Molecular immunology.

[5]  G. Hämmerling,et al.  Structural features of the invariant chain fragment CLIP controlling rapid release from HLA-DR molecules and inhibition of peptide binding. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  C. Lee,et al.  A general model of invariant chain association with class II major histocompatibility complex proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Weber,et al.  DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. , 1995, Immunity.

[8]  P. Cresswell,et al.  HLA-DM induces clip dissociation from MHC class II αβ dimers and facilitates peptide loading , 1995, Cell.

[9]  D. Zaller,et al.  Mediation by HLA-DM of dissociation of peptides from HLA-DR , 1995, Nature.

[10]  V. Gnau,et al.  Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules , 1995, The Journal of experimental medicine.

[11]  A Sette,et al.  Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II , 1995, The Journal of experimental medicine.

[12]  H. Mcdevitt,et al.  Binding of an invariant-chain peptide, CLIP, to I-A major histocompatibility complex class II molecules. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Wiley,et al.  Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. , 1994, Science.

[14]  P. Cresswell,et al.  In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. , 1994, Immunity.

[15]  Emil R. Unanue,et al.  Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell , 1994, Nature.

[16]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[17]  R. Germain,et al.  The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy , 1994, The Journal of experimental medicine.

[18]  H. Ploegh,et al.  Mapping functional regions in the lumenal domain of the class II- associated invariant chain , 1994, The Journal of experimental medicine.

[19]  J. Strominger,et al.  Selective release of some invariant chain-derived peptides from HLA-DR1 molecules at endosomal pH , 1994, The Journal of experimental medicine.

[20]  V. Reyes,et al.  Cathepsin B cleavage and release of invariant chain from MHC class II molecules follow a staged pattern. , 1994, Molecular immunology.

[21]  C Oseroff,et al.  HLA-DR3 molecules can bind peptides carrying two alternative specific submotifs. , 1994, Journal of immunology.

[22]  H. Ploegh,et al.  Isolation and characterization of the intracellular MHC class II compartment , 1994, Nature.

[23]  Don C. Wiley,et al.  Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen , 1994, Nature.

[24]  B. Arp,et al.  HLA-DMA and -DMB genes are both required for MHC class II/peptide complex formation in antigen-presenting cells , 1994, Nature.

[25]  Jeffrey A. Shaman,et al.  An essential role for HLA–DM in antigen presentation by class II major histocompatibility molecules , 1994, Nature.

[26]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[27]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[28]  L. Smith,et al.  A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides , 1994, The Journal of experimental medicine.

[29]  P. Cresswell,et al.  Assembly, transport, and function of MHC class II molecules. , 1994, Annual review of immunology.

[30]  N. Koch,et al.  The segment of invariant chain that is critical for association with major histocompatibility complex class II molecules contains the sequence of a peptide eluted from class II polypeptides. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  V. Gnau,et al.  Natural peptide ligand motifs of two HLA molecules associated with myasthenia gravis. , 1993, International immunology.

[32]  D. Wiley,et al.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.

[33]  William Arbuthnot Sir Lane,et al.  Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles , 1993, The Journal of experimental medicine.

[34]  R. Germain,et al.  Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules , 1993, Nature.

[35]  S. Ceman,et al.  Invariant chain peptides in most HLA-DR molecules of an antigen-processing mutant. , 1992, Science.

[36]  P. Cresswell,et al.  HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides , 1992, Nature.

[37]  Dean R. Madden,et al.  The three-dimensional structure of HLA-B27 at 2.1 Å resolution suggests a general mechanism for tight peptide binding to MHC , 1992, Cell.

[38]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[39]  D. Wiley,et al.  The human class II MHC protein HLA-DR1 assembles as empty αβ heterodimers in the absence of antigenic peptide , 1992, Cell.

[40]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[41]  K. Sharp,et al.  Protein folding and association: Insights from the interfacial and thermodynamic properties of hydrocarbons , 1991, Proteins.

[42]  R Langridge,et al.  Conic: a fast renderer for space-filling molecules with shadows. , 1991, Journal of molecular graphics.

[43]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[44]  J. Gorski,et al.  Transfer of polymorphic monoclonal antibody epitopes to the first and second domains of HLA-DR beta-chains by site-directed mutagenesis. , 1991, Journal of immunology.

[45]  D. Wiley,et al.  Crystallization of HLA-DR antigens. , 1991, Research in immunology.

[46]  B. Arp,et al.  Defective processing and presentation of exogenous antigens in mutants with normal HLA class II genes , 1990, Nature.

[47]  J. Strominger,et al.  Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. , 1987, The Journal of biological chemistry.

[48]  W. Kabsch.  A discussion of the solution for the best rotation to relate two sets of vectors , 1978 .

[49]  V. Luzzati,et al.  Traitement statistique des erreurs dans la determination des structures cristallines , 1952 .